Evaluation of Efficacy and Safety of Low-Fluence Q-Switched 1064-nm Laser in Infra-orbital Hyperpigmentation Based on Biometric Parameters Efficacy of Low-Fluence Q-Switched 1064-nm Laser in Infra-orbital Hyperpigmentation
Journal of Lasers in Medical Sciences,
Vol. 13 (2022),
10 January 2022
,
Page e16
Abstract
Introduction: Dark circles and wrinkles under the eyes are common cosmetic problems, caused by various conditions, especially aging and overproduction of melanin in the epidermis or dermis of the skin. In addition to the application of topical lightening agents, different types of lasers, especially the Q-Switched ND:YAG laser, has been used for the treatment of cutaneous hyperpigmentation. Because of a high prevalence of idiopathic eye dark circles (EDCs) or periorbital melanosis and a poor response to available therapies, we decided to evaluate the efficacy and safety of the Fractional QS 1064 nm ND:YAG Laser through a before-after trial.
Methods: 18-65-year-old patients with skin Fitzpatrick phototype of I-V and without any usage of a topical or systemic therapeutic regimen (2-4 weeks before the trial) were enrolled in the study. Each patient was treated with 6 sessions of the Fractional QS 1064 nm ND:YAG Laser at 2-week intervals and assessed for response and possible side effects or recurrences through 4 outcome measures, including Visoface-based color and erythema, melanin index and lightness (Before the fourth and sixth sessions of the therapy; also 1 week and 3 months after finishing the trial).
Results: The changes in Visoface-based color and erythema, the melanin pigment amount by the Mexameter (melanin index) and the degree of lightness by the Colorimeter of patients after 6 months of intervention were statistically significant (P<0.001).
Conclusion: The fractional QS 1,064 nm ND: YAG Laser is an effective and safe therapy in EDCs since objective outcomes like the reduction of the melanin index and improving lightness and subjective ones like the reduction of darkness and erythema were confirmed.
Doi:10.34172/jlms.2022.16.
- Eyelids dark circle; Periorbital hypermelanosis; Q-switched 1064-nm laser; Hyperpigmentation; Hypermelanosis.
How to Cite
References
Mitsuishi T, Shimoda T, Mitsui Y, Kuriyama Y, Kawana S. The effects of topical application of phytonadione, retinol and vitamins C and E on infraorbital dark circles and wrinkles of the lower eyelids. J Cosmet Dermatol. 2004;3(2):73-75. doi:10.1111/j.1473-2130.2004.00070.x.
Huang YL, Chang SL, Ma L, Lee MC, Hu S. Clinical analysis and classification of dark eye circle. Int J Dermatol. 2014;53(2):164-170. doi:10.1111/j.1365- 4632.2012.05701.x
Sarkar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmentation: what is available? J Cutan Aesthet Surg. 2013;6(1):4-11. doi:10.4103/0974-2077.110089
Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol. 2009;54(4):303- 309. doi:10.4103/0019-5154.57602
Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20-31.
Desai SR. Hyperpigmentation therapy: a review. J Clin Aesthet Dermatol. 2014;7(8):13-17.
Saedi N, Ganesan AK. Treating hyperpigmentation in darker-skinned patients. J Drugs Dermatol. 2013;12(5):563-567. 8. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin
Cutan Med Surg. 2009;28(2):77-85. doi:10.1016/j.sder.2009.04.001
Na SY, Cho S, Lee JH. Intense pulsed light and low-fluence Q-switched Nd: YAG laser treatment in melasma patients. Ann Dermatol. 2012;24(3):267-273. doi:10.5021/ad.2012.24.3.267
Ho S, Yeung C, Chan N, Shek S, Kono T, Chan H. A retrospective analysis of the management of acne post‐inflammatory hyperpigmentation using topical treatment, laser treatment, or combination topical and laser treatments in oriental patients. Lasers Surg Med. 2011;43(1):1-7. doi:10.1002/lsm.21010
Kim S, Cho Kh. Treatment of procedure‐related postinflammatory hyperpigmentation using 1064‐nm Q‐switched Nd: YAG laser with low fluence in Asian patients: report of five cases. J Cosmet Dermatol. 2010;9(4):302-306. doi:10.1111/j.1473-2165.2010.00527.x
Arora P, Sarkar R, Garg VK, Arya L. Lasers for treatment of melasma and post- inflammatory hyperpigmentation. J Cutan Aesthet Surg. 2012;5(2):93-103. doi:10.4103/0974-2077.99436
Oram Y, Akkaya AD. Refractory postinflammatory hyperpigmentation treated fractional CO2 laser. J Clin Aesthet Dermatol. 2014;7(3):42-44.
Zawar VP, Agarwal M, Vasudevan B. Treatment of Postinflammatory Pigmentation Due to Acne with Q-Switched Neodymium-Doped Yttrium Aluminum Garnet In 78 Indian Cases. J Cutan Aesthet Surg. 2015;8(4):222-226. doi:10.4103/0974-2077.172196
Rivas S, Pandya AG. Treatment of melasma with topical agents, peels and lasers: an evidence-based review. Am J Clin Dermatol. 2013;14(5):359-376. doi:10.1007/s40257-013-0038-4
Sofen B, Prado G, Emer J. Melasma and post inflammatory hyperpigmentation: management update and expert opinion. Skin Therapy Lett. 2016;21(1):1-7.
Morais OOd, Lemos ÉFL, Sousa MCdS, Gomes CM, Costa IMC, Paula CDRd. The use of ablative lasers in the treatment of facial melasma. An Bras Dermatol. 2013;88(2):238-242. doi:10.1590/S0365-05962013000200009
Kim YJ, Whang KU, Choi WB, Kim HJ, Hwang JY, Lee JH, et al. Efficacy and safety of 1,064 nm Q-switched Nd: YAG laser treatment for removing melanocytic nevi. Ann Dermatol. 2012;24(2):162-167. doi:10.5021/ad.2012.24.2.162
Sahni K, Kassir M. Dermafrac™: An innovative new treatment for periorbital melanosis in a dark-skinned male patient. J Cutan Aesthet Surg. 2013;6(3):158-160. doi:10.4103/0974-2077.118420
Nilforoushzadeh MA, Alavi S, Heidari‐Kharaji M, Hanifnia AR, Mahmoudbeyk M, Karimi Z, et al. Biometric changes of skin parameters in using of microneedling fractional radiofrequency for skin tightening and rejuvenation facial. Skin Res Technol. 2020;26(6):859-66. doi.org/10.1111/srt.12887
Nilforoushzadeh MA, Zolghadr S, Heidari-Kharaji M, Alavi S, Mahmoudbeyk M. A comparative study of the efficacy of fractional neodymium-doped yttrium aluminum garnet (Nd: YAG) laser therapy alone and in combination with erbium: YAG laser therapy: tracing and objective measurement of melanin index in macular amyloidosis. Lasers Med Sci. 2020;35(5):1171-1177. doi:10.1007/s10103-020-02954-y
Alavi S, Abolhasani E, Asadi S, Nilforoushzadeh M. Combination of Q-switched Nd: YAG and fractional Erbium: YAG lasers in treatment of melasma: a randomized controlled clinical trial. J Lasers Med Sci. 2017;8(1):1-6.
doi:10.15171/jlms.2017.01
Parver DL, Dreher RJ, Kohanim S, Zimmerman P, Garrett G, Devisetty L, et al. Ocular injury after laser hair reduction treatment to the eyebrow. Arch Ophthalmol. 2012;130(10):1330-1334. doi:10.1001/archophthalmol.2012.1988
Momosawa A, Kurita M, Ozaki M, Miyamoto S, Kobayashi Y, Ban I, et al. Combined Therapy Using Q-Switched Ruby Laser and Bleaching Treatment with Tretinoin and Hydroquinone for Periorbital Skin Hyperpigmentation in Asians. Plast Reconstr Surg. 2008;121(1):282-288. doi:10.1097/01.prs.0000293869.00522.ec
Michelle L, Foulad DP, Ekelem C, Saedi N, Mesinkovska NA. Treatments of periorbital hyperpigmentation: A systematic review. Dermatol Surg. 2021;47(1):70-74. doi:10.1097/DSS.0000000000002484
Eberlin S, Del Carmen Velazquez Pereda M, de Campos Dieamant G, Nogueira C, Werka RM, de Souza Queiroz ML. Effects of a Brazilian herbal compound as a cosmetic eyecare for periorbital hyperchromia (“dark circles”). J Cosmet Dermatol. 2009;8(2):127-35.
Watanabe S, Nakai K, Ohnishi T. Condition Known as “Dark Rings Under the Eyes” in the Japanese Population is a Kind of Dermal Melanocytosis Which can be Successfully Treatedby Q‐Switched Ruby Laser. Dermatol Surg. 2006;32(6):785-9. doi:10.1111/j.1524-4725.2006.32161.x
WEST TB, ALSTER TS. Improvement of Infraorbital Hyperpigmentation following Carbon Dioxide Laser Resurfacing. Dermatol Surg.1998;24(6):615-6. doi:10.1111/j.1524-4725.1998.tb04216.x
Roh MR, Chung KY. Infraorbital dark circles: definition, causes, and treatment options. Dermatol Surg. 2009;35(8):1163-71. doi:10.1111/j.1524-4725.2009.01213.x
Freitag FM, Cestari TF. What causes dark circles under the eyes? J Cosmet Dermatol. 2007;6(3):211-5. doi:10.1111/j.1473-2165.2007.00324.x
Pissaridou MK, Ghanem A, Lowe N. Periorbital Discolouration Diagnosis and Treatment: Evidence-Based Review. J Cosmet Laser Ther. 2020;22(6-8):217-225. doi:10.1080/14764172.2021.1899238
Saad A. News in the treatment of periorbital hyperpigmentation. J Dermatol & Ther. 2017;1(106):20-3.
Omi T, Yamashita R, Kawana S, Sato S, Naito Z. Low Fluence Q-Switched Nd: YAG Laser Toning and Q-Switched Ruby Laser in the Treatment of Melasma:A Comparative Split-Face Ultrastructural Study. Laser Ther. 2012;21(1):15-21. doi:10.5978/islsm.12-OR-03
Cymbalista N, Torezan L, Osorio N, Mattos R, Valente N, editors. Treatment Of Eyelid Hyperpigmentation With Qs Ruby Laser And Intense Pulsed Light Device. Lasers Surg Med. 2002;30:66.
Ustuner P, Balevi A, Ozdemir M. A split-face, investigator-blinded comparative study on the efficacy and safety of Q-switched Nd:YAG laser plus microneedling with vitamin C versus Q-switched Nd:YAG laser for the treatment of recalcitrant melasma. J Cosmet Laser Ther. 2017;19(7):383-390. doi:10.1080/14764172.2017.1342036
XU TH, YANG ZH, LI YH, Chen JZ, Guo S, Wu Y, et al. Treatment of infraorbital dark circles using a low‐fluence Q‐switched 1,064‐nm laser. Dermatol Surg. 2011;37(6):797-803. doi:10.1111/j.1524-4725.2011.01956..x
Agrawal S. Periorbital hyperpigmentation: Overcoming the challenges in the management. Nepal J Dermatol, Venereol Leprol. 2018;16(1):2-11.
Nilforoushzadeh MA, Heidari-Kharaji M, Alavi S, Zolghadr S, Mahmoudbeyk M, Nikkhah N. Comparison of carboxy therapy and fractional Q-switched ND: YAG laser on periorbital dark circles treatment: a clinical trial. Lasers Med Sci. 2021;36(9):1927- 1934. doi:10.1007/s10103-021-03274-5
Mhatre M, Malkud S, Mysore V. Efficacy and safety of Q-switched Nd: YAG laser in the treatment of facial pigmentary lesions: A retrospective observational study. Iran J Dermatol. 2021;24(1):24-31.
Lajevardi V, Ghayoumi A, Abedini R, Hosseini H, Goodarzi A, Akbari Z, et al.
Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel‐group, assessor‐and analyst‐blinded, randomized controlled trial with a short‐term follow‐up. J Cosmet Dermatol. 2017;16(2):235-242. doi:10.1111/jocd.12291
Behrangi E, Baniasadi F, Esmaeeli S, Hedayat K, Goodarzi A, Azizian Z. Serum iron level, ferritin and total iron binding capacity level among nonpregnant women with and without melasma. J Res Med Sci. 2015;20(3):281-283.
Goodarzi A, Behrangi E, Sadeghzadeh-Bazargan A, Roohaninasab M, Hosseini- Baharanchi FS, Shemshadi M, et al. The association between melasma and iron profile: a case-control study. Russ Open Med J. 2020;9(2):1-5.doi:10.15275/rusomj.2020.0202
Ehsani A, Noormohammadpour P, Goodarzi A, Shahshahani MM, Hejazi SP, Hosseini E, et al. Comparison of long-pulsed alexandrite laser and topical tretinoin-ammonium lactate in axillary acanthosis nigricans: A case series of patients in a before-after trial. Caspian J Intern Med. 2016;7(4):290-293.
Roohaninasab M, Sadeghzadeh-Bazargan A, Goodarzi A. Effects of laser therapy on periorbital hyperpigmentation: a systematic review on current studies. Lasers Med Sci. 2021;36(9):1781-1789. doi:10.1007/s10103-020-03241-6
Ghassemi M, Hosseinchi S, Seirafianpour F, Dodangeh M, Goodarzi A. Non‐alcoholic fatty liver and lipid profile status in patients with melasma: A case‐control study. J Cosmet Dermatol. 2021;20(11):3656-3660. doi:10.1111/jocd.14014
- Abstract Viewed: 766 times
- PDF Downloaded: 436 times